Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.

Date publication

janvier 2026

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Goss GD, Darling GE, Westeel V, Nakagawa K, Massutí B, Perrone F, McLachlan SA, Kang JH, Wu YL, Dingemans AC, Dziadziuszko R, Greillier L, Okada M, Audigier-Valette C, Sugawara S, Nadal E, Catino A, Toffart AC, Mitsudomi T, Whittom R, Domine M, Yamamoto N, Molinier O, Morin F, Bradbury PA, Stockler MR, Ding K, O'Callaghan CJ

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41529222

Résumé

Adjuvant immunotherapy improved patient outcomes in two trials in completely resected non-small cell lung cancer (NSCLC), but with conflicting primary end point results. The Canadian Cancer Trials Group BR.31 trial evaluated adjuvant durvalumab in completely resected early-stage NSCLC.

Référence

J Clin Oncol. 2026 01 13;:JCO2501828